KPL

Kwality Pharmaceuticals Limited delivered a landmark FY26, achieving its highest-ever quarterly and annual revenues. Q4 FY26 revenue grew 35.8% to ₹157.1 crores, while full-year revenue increased by 35.9% to ₹503 crores from ₹370 crores in FY25. Profitability also saw significant improvement, with EBITDA margins expanding from 22% to 24% and PAT growing 67.5% to ₹67 crores. The company has set ambitious targets, aiming for ₹650 crores in revenue and ₹100 crores PAT in FY27, with a long-term aspiration of ₹1,000 crores revenue by FY29.

The company is strategically shifting its focus towards regulated markets, expecting 7-8 registrations by the end of calendar year 2027. Products in these regulated markets are anticipated to yield roughly 40% EBITDA margins, significantly higher than current averages. This shift is projected to drive overall EBITDA margins to 26-27% in FY27, 28% in FY28, and 30% in FY29. Gross margins are also expected to improve from 49% in FY26 to 52-53% in FY27 as regulated market sales increase.

Oncology revenue for FY26 was approximately ₹100 crores, with a projection to increase to ₹150 crores in FY27 and ₹300 crores by FY29, contributing 30% to the total FY29 revenue. The company is investing significantly in biosimilars, with a total capex of ₹260-270 crores planned for hormones, oncology, biosimilar R&D, and bioequivalence studies over FY27-FY28. Initial biosimilar products are expected to yield 40-45% EBITDA margins, normalizing to 25-30% in the long term, with submissions for Erythropoietin in 50 countries planned for Q4 FY27.

Kwality Pharma plans a total capex of ₹260-270 crores for various projects, with ₹46 crores already spent in FY26, and ₹90 crores allocated for FY27 and ₹90-100 crores for FY28. This capex is being funded through existing working capital and re-utilization of bank loans without increasing overall borrowings. The cash conversion cycle has improved from 208 days to 170 days, and management expects further improvements, with debtor days targeted at 150-160 days, ensuring sufficient cash flows for capex from internal accruals.

The company's ₹1,000 crore revenue target by FY29 is supported by a diversified geographic strategy. LATAM is expected to contribute 30% of revenue, Algeria and other MENA regions 15%, French West Africa 10%, and GCC 10-15%. Russia is projected to contribute 5-7% of total sales. The domestic market, currently focused on peptide-based products (₹40-50 crores), is expected to grow by 10-15%.

Kwality Pharma is increasing its R&D spend from 2% to 5-6% of revenues, focusing on in-house R&D for oncology, general items, cephalosporin, beta-lactam, and upcoming hormone products. The strategy involves developing off-patent or soon-to-be-off-patent products to gain initial mover advantage and higher margins. The company plans to continuously add 10-20 new bioequivalence products annually to replace older molecules and sustain growth.